Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Non-Current Debt (2016 - 2025)

Immucell (ICCC) has disclosed Non-Current Debt for 16 consecutive years, with $7.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Debt fell 16.18% year-over-year to $7.9 million, compared with a TTM value of $7.9 million through Sep 2025, down 16.18%, and an annual FY2024 reading of $9.0 million, down 14.23% over the prior year.
  • Non-Current Debt was $7.9 million for Q3 2025 at Immucell, down from $8.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $10.9 million in Q3 2023 and bottomed at $7.9 million in Q3 2025.
  • Average Non-Current Debt over 5 years is $9.2 million, with a median of $9.0 million recorded in 2024.
  • The sharpest move saw Non-Current Debt grew 16.78% in 2022, then decreased 16.18% in 2025.
  • Year by year, Non-Current Debt stood at $8.3 million in 2021, then grew by 10.38% to $9.2 million in 2022, then grew by 14.68% to $10.5 million in 2023, then decreased by 14.23% to $9.0 million in 2024, then dropped by 12.63% to $7.9 million in 2025.
  • Business Quant data shows Non-Current Debt for ICCC at $7.9 million in Q3 2025, $8.3 million in Q2 2025, and $8.7 million in Q1 2025.